Table 1.
Characteristics of Patients with Chronic Ocular Graft-Versus-Host Disease
| No. | Age | Sex | Diagnosis | Time from SCT to dry eye | cGVHD other than eyes | Systemic immunosuppressant | Follow-up after allogeneic serum |
|---|---|---|---|---|---|---|---|
| 1 | 31 | F | AML | 4 | Oral, Lung | Steroid | 24 |
| 2 | 51 | M | CLL | 12 | Oral, GI | Steroid | 12 |
| 3 | 46 | M | ALL | 6 | 6 | ||
| 4 | 61 | F | ALL | 12 | Oral | 6 | |
| 5 | 37 | M | MDS | 5 | 5 | ||
| 6 | 30 | M | ALL | 11 | Oral | Steroid | 4 |
| 7 | 45 | M | CML | 16 | Lung, GI | Steroid | 9 |
| 8 | 41 | M | AML | 25 | GI | Steroid | 6 |
| 9 | 27 | M | AML | 13 | Oral | 8 | |
| 10 | 47 | M | AML | 12 | Oral | Steroid | 12 |
| 11 | 45 | F | AML | 6 | Oral | Steroid | 24 |
| 12 | 37 | F | AML | 8 | Oral, Skin, GI | Steroid, CsA | 18 |
| 13 | 25 | M | AML | 4 | Oral, Skin | Steroid | 17 |
| 14 | 21 | M | AML | 5 | Skin | 3 | |
| 15 | 31 | F | AML | 7 | 11 | ||
| 16 | 20 | F | AML | 10 | Oral, GI | Steroid | 20 |
SCT, stem cell transplantation; cGVHD, chronic graft-versus-host disease; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; CsA, cyclosporine A.